73 results
Page 3 of 4
8-K
EX-99.1
9irhp
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-99.1
479d5jh 9q2p
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-99.1
9zhapcw5
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.2
xs7pujzish8i tjv
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
6wzwsto9vexr3h8nt
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-99.1
4um5c
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
69v4rhu eqh
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.2
ax1z42z
1 Jun 20
Entry into a Material Definitive Agreement
7:01am
8-K
EX-99.1
9u3h23iq
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
8-K
EX-99.1
a5n6x fdtq9ipb52h
17 Mar 20
Processa Pharmaceuticals Announces Results from the Phase 2 Study In Necrobiosis Lipoidica
9:30am
8-K
EX-99.1
9or c6za9t0gw
5 Mar 20
Processa Pharmaceuticals Announces Formation of Its Medical and Scientific Advisory Board
9:30am
8-K
EX-99.1
z3cr1cmoo6
25 Feb 20
Processa Pharmaceuticals Provides Shareholder Update
9:30am
8-K
EX-99.1
f14f dcgp4o1ar4kn0y
13 Feb 20
Processa Pharmaceuticals Appoints
9:30am
8-K
EX-99.1
7kf8g9m q2q
20 Dec 19
Processa Pharmaceuticals Announces 1 for 7 Reverse Stock Split of Its Common Stock
4:20pm
8-K
EX-99.2
siszt2sm
4 Sep 19
Entry into a Material Definitive Agreement
5:19pm